By Sheeba M. | March 31, 2026
Cannabis Rescheduling Update: DEA Hearing Reveals Deep Industry Divisions
The DEA’s administrative law judge wrapped the third and final week of rescheduling hearings with a record that reveals just how fractured the cannabis industry’s political coalition actually is. What looked like broad consensus for removing cannabis from Schedule I has fractured into competing visions: complete descheduling favored by large MSOs and financial institutions, versus a more cautious rescheduling-to-Schedule-III approach backed by state regulators concerned about regulatory capacity.
The Hearing’s Key Takeaways
The most significant development wasn’t a ruling — it was testimony from the Department of Health and Human Services, which acknowledged that its initial recommendation to move cannabis to Schedule III was based on a scientific review that did not fully account for potency data from modern cannabis products. This admission, buried in a footnote, has become a rallying point for rescheduling opponents.
On the industry side, Organigram (OGI)‘s CEO testified on the 280E tax burden as a core argument for rescheduling, presenting internal financials showing effective tax rates 40-60% above comparable consumer goods companies due to the scheduling status. That’s a compelling data point that even skeptical regulators have found difficult to dismiss.
The Banking Split
The financial services angle dominated Day 8 of hearings, with credit union and bank associations presenting data on the operational risks of cash-only cannabis businesses. Over 70% of state-licensed cannabis businesses remain cash-only, creating documented security risks that regulators cannot ignore. The SAFE Banking Act’s passage through committee earlier this year gave this argument new momentum.
But banking reform and rescheduling remain technically separate tracks — a point some DEA officials stressed repeatedly. Even if rescheduling occurs, cannabis businesses would remain illegal under federal law, technically making bank service a compliance liability rather than a protected activity.
What’s Next: Timeline and Scenarios
The DEA has 90 days from hearing conclusion to issue a final rule, putting a decision in late June 2026 at the earliest. Legal observers expect the rulemaking to face immediate court challenges regardless of outcome. Three scenarios are on the table:
Full Descheduling: cannabis removed from Controlled Substances Act entirely. Unlikely given HHS reservations and DEA’s historical posture. Would be the most bullish catalyst for valuations.
Reschedule to Schedule III: cannabis remains controlled but recognized medical utility. Opens 280E relief and banking services without resolving interstate commerce. Most likely outcome per industry counsel.
No Action / Remain Schedule I: DEA declines to reschedule based on hearing record. Would be a significant negative catalyst and likely trigger renewed legislative push.
Market Implications
MSOs have priced in modest rescheduling probability, with 2026 revenue multiples compressing relative to 2025 as the timeline has slipped. If Schedule III materializes, analysts project 15-25% valuation upside for vertically integrated operators with strong state-by-state margins — primarily because 280E relief is the single largest near-term earnings lever available to the sector.
For Green Thumb Industries (GTBIF) and Trulieve (TRUL), which have made significant cultivation infrastructure investments, Schedule III rescheduling would meaningfully improve free cash flow conversion without changing their competitive positioning — a rare event where the existing leaders benefit most.
Sources
- DEA Official Proceedings – Administrative hearing record March 2026
- FDA/HHS – Cannabis scheduling review documentation
Track These Stocks
Track cannabis stocks with the Weedstock Real-Time Tracker